Posts Tagged ‘Vanessa Almendro’

Categories

Posted in:

Monday June 17th, 2013

A population of cells which decreases after pregnancy is related to breast cancer risk

Epidemiological and experimental data suggest that full-term pregnancy (lasting 37 – 40 weeks) at an early age reduces the risk of developing breast cancer in postmenopausal women. However, the mechanism responsible for this protection is unknown. A study led by researchers at the Dana Farber Cancer Institute of the Harvard Medical School (Boston, USA), in collaboration with the Johns Hopkins University School of Medicine (Baltimore, USA), identifies molecular differences in breast cells from women with and without children. The work was published in the journal Cell Stem Cell from the Cell group, with Dr. Vanessa Almendro as its co-first author. Shes is a member of the IDIBAPS Molecular and Translational Oncology team directed by Dr. Pere Gascon, Chief of Oncology at the Hospital Clínic of Barcelona. The results of the investigation suggest that CD44+ p27+ cells are potential progenitors of estrogen receptor-positive (ER+) postmenopausal breast cancer, the most common form of the disease.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Thursday May 21st, 2009

Oxaliplatin Promotes the Survival of Drug-Resistant Colon Tumor Cells

Dr. Elisabet Ametller and Dr. Vanessa Almendro at Hospital Clínic

Oxaliplatin is a drug that is widely used to treat colon cancer, but its efficacy is limited by the development of resistance to chemotherapy of the tumor cells. The chemoresistant cells undergo molecular changes that protect them from the cell death induced by the drugs, thus re-establishing the processes of tumor progression. An article published in PLoS One analyzes the role of the metalloproteinase, MMP7, in the resistance mechanisms of these cells and its effect on the Fas receptor involved in promoting cell death by apoptosis. This study was directed by Dr. Vanessa Almendro of the department of medical oncology at Hospital Clínic-IDIBAPS and by Dr. Pere Gascón, and involved the collaboration of Dr. Elisabet Ametller, among others. The results show that, in colon cancer cell lines, MMP7 is directly related to the acquisition of resistance to oxaliplatin and its inhibition re-establishes sensitivity to the drug due to an increase in the Fas receptor. Furthermore, the authors observed that, surprisingly, the Fas receptor undergoes changes in functionality in cells resistant to oxaliplatin, leading it to induce survival signals instead of apoptotic signals.
Read the rest of this entry »

Comments Closed